{
    "clinical_study": {
        "@rank": "69033", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver\n      cancer-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating\n      patients with refractory anaplastic large cell lymphoma or Hodgkin's lymphoma."
        }, 
        "brief_title": "Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "December 2007", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Large-Cell, Anaplastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the safety and tolerability of multiple doses of monoclonal antibody HeFi-1\n           in patients with CD30+ anaplastic large cell lymphoma or Hodgkin's lymphoma.\n\n        -  Determine the pharmacokinetics of this drug in this patient population.\n\n        -  Evaluate the efficacy, in terms of correlating immunologic parameters and\n           immunogenicity, of this drug in these patients.\n\n      OUTLINE: This is an open-label, dose-escalation study.\n\n      Patients receive monoclonal antibody HeFi-1 IV over 30 minutes 3 times a week for 2 weeks.\n      Treatment may continue for 2 additional weeks in the absence of anti-HeFi-1 response.\n      Responding patients may continue treatment at monthly intervals for one year.\n\n      Cohorts of 3-4 patients receive escalating doses of monoclonal antibody HeFi-1 until the\n      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at\n      which 2 of 4 patients experience dose-limiting toxicity.\n\n      Patients are followed monthly.\n\n      PROJECTED ACCRUAL: A total of 9 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed CD30+ anaplastic large cell lymphoma (ALCL) or Hodgkin's\n             lymphoma\n\n               -  At least 50% of malignant cells must react with HeFi-1\n\n               -  HIV positive or HIV negative\n\n          -  Measurable disease\n\n          -  No symptomatic CNS disease\n\n          -  Must have failed or be ineligible for standard chemotherapy regimen\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  More than 2 months\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  No significant hepatic disease\n\n          -  Bilirubin no greater than 2 mg/dL\n\n        Renal:\n\n          -  No significant renal disease\n\n          -  Creatinine no greater than 3 mg/dL\n\n        Cardiovascular:\n\n          -  No significant cardiovascular disease\n\n        Pulmonary:\n\n          -  No significant pulmonary disease\n\n        Other:\n\n          -  No significant endocrine, rheumatologic, or allergic disease\n\n          -  No active clinical disease caused by cytomegalovirus (CMV), herpes simplex virus\n             (HSV) I, HSV II, hepatitis B, or tuberculosis\n\n          -  Not pregnant\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior murine antibody therapy\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy to measurable disease\n\n        Surgery:\n\n          -  Not specified\n\n        Other\n\n          -  At least 4 weeks since prior cytotoxic therapy to measurable disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003741", 
            "org_study_id": "BIDMC-97127", 
            "secondary_id": [
                "CDR0000066859", 
                "NEDH-97127", 
                "NCI-870", 
                "NCI-V99-1515"
            ]
        }, 
        "intervention": {
            "intervention_name": "monoclonal antibody HeFi-1", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "keyword": [
            "recurrent adult Hodgkin lymphoma", 
            "anaplastic large cell lymphoma"
        ], 
        "lastchanged_date": "June 25, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/BIDMC-97127"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02215"
                }, 
                "name": "Beth Israel Deaconess Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "HeFi-1 Antibody Therapy in Ki-1 and Hodgkin's Lymphomas, a Phase I Study", 
        "overall_official": {
            "affiliation": "Beth Israel Deaconess Medical Center", 
            "last_name": "Henry Koon, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003741"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beth Israel Deaconess Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1999", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2005"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess Medical Center": "42.358 -71.06"
    }
}